pf-5190457
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01247896)
Timeline
Indications
Mechanism of action
- Ghrelin receptorINVERSE AGONIST
GHSR inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1- Mol. weight
- 512.68 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3287218 ↗
Also known as
- 2-(2-methylimidazo(2,1-b)(1,3)thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1h-inden-1-yl)-2,7-diazaspiro(3.5)non-7-ylethanone
- pf-05190457
- pf-05190457
- pf-05190457
- pf-5190457
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02707055 | Phase 2 | Mar 2, 2016 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT02039349 | Phase 1 | Jan 3, 2014 | National Center for Advancing Translational Science (NCATS), National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Rhode Island |
| NCT01522807 | Phase 1 | Sep 1, 2011 | Pfizer |
| NCT01372163 | Phase 1 | Jul 1, 2011 | Pfizer |
| NCT01247896 | Phase 1 | Dec 1, 2010 | Pfizer |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 1 | 2010 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 2 | 2 | 2 | 2014 |
| National Center for Advancing Translational Science (NCATS) | Government | 1 | 0 | 1 | 2014 |
| University of Rhode Island | Academic/Hospital | 1 | 0 | 1 | 2014 |
4 organizations
Page 1 / 1